Efficacy and Safety of Inhaled Zanamivir in the Prevention of Influenza in Community-Dwelling, High-Risk Adult and Adolescent Subjects: A 28-day, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
- 1 August 2007
- journal article
- research article
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 29 (8), 1579-1590
- https://doi.org/10.1016/j.clinthera.2007.08.023
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Neuraminidase Inhibitors for InfluenzaNew England Journal of Medicine, 2005
- Influenza-Associated Hospitalizations in the United StatesJAMA, 2004
- Neuraminidase Sequence Analysis and Susceptibilities of Influenza Virus Clinical Isolates to Zanamivir and OseltamivirAntimicrobial Agents and Chemotherapy, 2003
- Efficacy of Zanamivir against Avian Influenza A Viruses That Possess Genes Encoding H5N1 Internal Proteins and Are Pathogenic in MammalsAntimicrobial Agents and Chemotherapy, 2001
- Inhaled Zanamivir for the Prevention of Influenza in FamiliesNew England Journal of Medicine, 2000
- Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trialThe Pediatric Infectious Disease Journal, 2000
- Clinical Efficacy and Safety of the Orally Inhaled Neuraminidase Inhibitor Zanamivir in the Treatment of Influenza: a Randomized, Double-blind, Placebo-controlled European StudyJournal of Infection, 2000
- Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infectionsThe Lancet, 1998
- 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitroAntimicrobial Agents and Chemotherapy, 1993
- Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985.American Journal of Public Health, 1987